Literature DB >> 29305414

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis.

Richa Manwani1, Darren Foard1, Shameem Mahmood1, Sajitha Sachchithanantham1, Thirusha Lane1, Cristina Quarta1, Taryn Youngstein1, Tamer Rezk1, Helen J Lachmann1, Julian D Gillmore1, Marianna Fontana1, Carol Whelan1, Philip N Hawkins1, Ashutosh Wechalekar2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29305414      PMCID： PMC5865426          DOI： 10.3324/haematol.2017.178095

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

Authors:  Gregory P Kaufman; Stanley L Schrier; Richard A Lafayette; Sally Arai; Ronald M Witteles; Michaela Liedtke
Journal:  Blood       Date:  2017-06-14       Impact factor: 22.113

2.  Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Authors:  Arnaud Jaccard; Raymond L Comenzo; Parameswaran Hari; Philip N Hawkins; Murielle Roussel; Pierre Morel; Margaret Macro; Jean-Luc Pellegrin; Estibaliz Lazaro; Dania Mohty; Patrick Mercie; Olivier Decaux; Julian Gillmore; David Lavergne; Frank Bridoux; Ashutosh D Wechalekar; Christopher P Venner
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

3.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Stefan O Schonland; Efstathios Kastritis; Julian D Gillmore; Meletios A Dimopoulos; Thirusha Lane; Andrea Foli; Darren Foard; Paolo Milani; Lisa Rannigan; Ute Hegenbart; Philip N Hawkins; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood       Date:  2013-03-11       Impact factor: 22.113

Review 4.  Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

Authors:  R L Comenzo; D Reece; G Palladini; D Seldin; V Sanchorawala; H Landau; R Falk; K Wells; A Solomon; A Wechalekar; J Zonder; A Dispenzieri; M Gertz; H Streicher; M Skinner; R A Kyle; G Merlini
Journal:  Leukemia       Date:  2012-04-05       Impact factor: 11.528

5.  Guidelines on the management of AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Julian D Gillmore; Jenny Bird; Jamie Cavenagh; Stephen Hawkins; Majid Kazmi; Helen J Lachmann; Philip N Hawkins; Guy Pratt
Journal:  Br J Haematol       Date:  2014-10-10       Impact factor: 6.998

Review 6.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

7.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Authors:  Shaji Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Colin Colby; Kristina Laumann; Steve R Zeldenrust; Nelson Leung; David Dingli; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

8.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Philip R Greipp; Thomas E Witzig; John A Lust; S Vincent Rajkumar; Rafael Fonseca; Steven R Zeldenrust; Christopher G A McGregor; Allan S Jaffe
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

Review 9.  Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Authors:  G Merlini; I Lousada; Y Ando; A Dispenzieri; M A Gertz; M Grogan; M S Maurer; V Sanchorawala; A Wechalekar; G Palladini; R L Comenzo
Journal:  Leukemia       Date:  2016-07-15       Impact factor: 11.528

10.  Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody.

Authors:  Morie A Gertz; Heather J Landau; Brendan M Weiss
Journal:  Am J Hematol       Date:  2016-10-21       Impact factor: 10.047
  10 in total
  14 in total

Review 1.  Systemic amyloidosis: moving into the spotlight.

Authors:  Oliver C Cohen; Ashutosh D Wechalekar
Journal:  Leukemia       Date:  2020-04-09       Impact factor: 11.528

2.  Management of AL amyloidosis in 2020.

Authors:  Giovanni Palladini; Paolo Milani; Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 3.  AL amyloidosis: untangling new therapies.

Authors:  Susan Bal; Heather Landau
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center.

Authors:  Victor H Jimenez-Zepeda; Holly Lee; Nowell Fine; Sylvia McCulloch; Jason Tay; Peter Duggan; Paola Neri; Nizar Bahlis
Journal:  Indian J Hematol Blood Transfus       Date:  2021-02-17       Impact factor: 0.915

Review 5.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

6.  Approach to a patient with cardiac amyloidosis.

Authors:  Christopher Strouse; Alexandros Briasoulis; Rafael Fonseca; Yogesh Jethava
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

7.  Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.

Authors:  Sriram Ravichandran; Oliver C Cohen; Steven Law; Darren Foard; Marianna Fontana; Ana Martinez-Naharro; Carol Whelan; Julian D Gillmore; Helen J Lachmann; Sajitha Sachchithanantham; Shameem Mahmood; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood Cancer J       Date:  2021-06-21       Impact factor: 11.037

Review 8.  Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.

Authors:  Mathew S Maurer; Preston Dunnmon; Mariana Fontana; Cristina Candida Quarta; Krishna Prasad; Ronald M Witteles; Claudio Rapezzi; James Signorovitch; Isabelle Lousada; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2022-03-25       Impact factor: 10.447

Review 9.  Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis.

Authors:  Yiu Ming Khor; Sarah Cuddy; Rodney H Falk; Sharmila Dorbala
Journal:  Semin Nucl Med       Date:  2020-02-09       Impact factor: 4.802

Review 10.  Future Perspectives.

Authors:  Angela Dispenzieri; Giampaolo Merlini
Journal:  Hematol Oncol Clin North Am       Date:  2020-12       Impact factor: 3.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.